Exidavnemab phase 2a study expanded to include MSA patients
Go back to Exidavnemab phase 2a study expanded to include MSA patients| BARNES GROUP, Inc. (NYSE: B) | Delayed: 42.88 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.88 | 52 Week High | $44.27 | |||
| Open | $42.88 | 52 Week Low | $30.07 | |||
| Day High | $42.88 | P/E | 32.73 | |||
| Day Low | $42.88 | EPS | $1.31 | |||
| Volume | 151,515 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 7.05 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.05 | 52 Week High | $8.73 | |||
| Open | $7.05 | 52 Week Low | $2.86 | |||
| Day High | $7.05 | P/E | N/A | |||
| Day Low | $7.05 | EPS | $-3.82 | |||
| Volume | 262 | |||||
